Abstract
Intravesical administration of live M. bovis BCG organisms for carcinoma in situ of the urinary bladder is the most successful immunotherapy for solid malignancy. Nevertheless BCG-therapy is associated with significant toxicity and is ineffective in 30-40% of cases. Recently it has been proposed that cytokine-modified mycobacteria may give greater efficacy. As any immunotherapy involving administration of live BCG organisms (wild-type or recombinant) is likely to have associated toxicity (notably in the immunocompromised), we examined the anti-tumour potential of the closely related nonpathogenic organism, Mycobacterium smegmatis, and a TNFalpha gene-modified recombinant M. smegmatis. When wild-type M. smegmatis were delivered to immunocompetent C57Bl/6 mice bearing the transplantable MB49 bladder tumour, efficacy comparable to live BCG was observed with 10-20% long-term survival. However, this effect was lost in both Nude and Beige mice, lacking functional T and NK cells, respectively. Recombinant M. smegmatis secreting TNFalpha, however, gave a 70% durable tumour-free survival. Lymphocytes from draining lymph-nodes and spleens of these mice exhibited pronounced IFNgamma production to mycobacterial-antigen and tumour-lysate, i...Continue Reading
Citations
Jun 21, 2012·Cancer Immunology, Immunotherapy : CII·Fenella J RichJoanna R Kirman
Jan 28, 2006·Journal of Virology·Mark J CayabyabNorman L Letvin
Sep 24, 2011·Clinical & Developmental Immunology·Yi LuoMichael A O'Donnell
Nov 20, 2013·PloS One·Ana Paula Junqueira-KipnisAndré Kipnis
Jul 20, 2010·Immunotherapy·Anton B AlexandroffAndrew M Jackson
Dec 1, 2015·Frontiers in Pharmacology·Sumanpreet Kaur, Sukhraj Kaur
Oct 10, 2015·Oncoimmunology·Sabine KuhnFranca Ronchese
Mar 22, 2015·Applied Microbiology and Biotechnology·K R BegniniF K Seixas
Feb 25, 2005·Journal of Leukocyte Biology·José M Martín-FernándezJosé R Regueiro
Feb 7, 2020·PloS One·Hussain A SafarAhmed El-Hashim
Sep 1, 2006·Clinical and Vaccine Immunology : CVI·Jae-Sung YuBarton F Haynes
May 3, 2013·PloS One·Russell S TaichmanKenneth J Pienta
Jun 1, 2016·Cardiovascular Therapeutics·Vrushali DeshpandeLakshmi A Mundkur
Jun 26, 2020·Frontiers in Immunology·Nisha KannanTrude Helen Flo
Sep 7, 2018·Experimental and Therapeutic Medicine·Wen JianYing Xue
Jul 17, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sabine KuhnFranca Ronchese
Jul 11, 2018·Frontiers in Cellular and Infection Microbiology·Xinwei FengGe Zhang
Dec 3, 2020·Pathogens·Nur-Ayuni KadirMohd-Nor Norazmi
Nov 8, 2008·The Journal of Organic Chemistry·Bert Fraser-ReidChangalvala V S Ramamurty
Jun 5, 2021·Investigative and Clinical Urology·Hyung Suk Kim, Ho Kyung Seo
Aug 15, 2021·Journal for Immunotherapy of Cancer·Hyein JeongBum-Joon Kim